Lung Protein rhCC16 Reverses Cellular Aging in COPD via Key Longevity Pathway
A natural airway protein slows cigarette smoke-driven cellular senescence by targeting the PI3K-AKT-mTOR pathway, offering a new COPD therapy angle.
Summary
Researchers found that recombinant human CC16 (rhCC16), a protein normally secreted by airway cells, can counteract cigarette smoke-induced cellular senescence in both lab and animal models of COPD. When lung cells were exposed to cigarette smoke extract, senescence markers increased sharply — but rhCC16 treatment suppressed these markers by inhibiting the PI3K-AKT-mTOR pathway and restoring autophagy, the cell's self-cleaning system. In mice with CS-induced COPD, intranasal rhCC16 improved lung function and reduced tissue damage. The protein appears to enter cells via integrin α4β1 receptors and clathrin-mediated endocytosis, suggesting a specific mechanism of action that could be targeted therapeutically.
Detailed Summary
Chronic obstructive pulmonary disease (COPD) affects hundreds of millions globally, and cigarette smoke remains its leading cause. One underappreciated mechanism linking smoke exposure to lung decline is cellular senescence — a state where damaged cells stop dividing but remain metabolically active, driving chronic inflammation and tissue destruction. This study explores whether restoring a naturally depleted lung protein can interrupt that process.
CC16, produced by club cells lining the airways, is known to be reduced in COPD patients. The research team tested whether supplementing this protein in its recombinant human form (rhCC16) could reverse smoke-induced aging at the cellular level. They exposed A549 alveolar epithelial cells to cigarette smoke extract and treated them with rhCC16, then measured established senescence biomarkers.
The results were striking. rhCC16 suppressed senescence markers in cell culture and, critically, inhibited the PI3K-AKT-mTOR signaling axis — a pathway central to aging, cellular metabolism, and longevity research. It also restored autophagic flux, meaning cells regained their ability to clear damaged components. Entry of rhCC16 into cells appeared to depend on integrin α4β1 receptors and clathrin-coated vesicle uptake.
In CS-exposed mice, intranasal delivery of rhCC16 improved measurable pulmonary function and reduced pathological lung injury seen on tissue analysis, suggesting translational potential beyond the lab dish.
These findings position rhCC16 as a candidate senolytic-adjacent therapy — not killing senescent cells, but preventing their accumulation in the first place. However, the study relies on animal and cell models; human clinical validation is needed. The long-term safety, optimal dosing, and delivery method of intranasal rhCC16 in humans remain to be established.
Key Findings
- rhCC16 suppressed cigarette smoke-induced cellular senescence markers in A549 alveolar epithelial cells.
- Anti-senescence effects were linked to inhibition of the PI3K-AKT-mTOR pathway and restored autophagic flux.
- rhCC16 enters lung cells via integrin α4β1 receptors and clathrin-mediated endocytosis.
- Intranasal rhCC16 improved pulmonary function and reduced lung tissue damage in CS-exposed mice.
- Findings suggest rhCC16 may be a senescence-targeted therapeutic candidate for COPD.
Methodology
In vitro senescence was modeled by exposing A549 human alveolar epithelial cells to cigarette smoke extract, with senescence markers quantified with and without rhCC16 treatment. A chronic CS-exposure mouse model of COPD was used for in vivo validation, with rhCC16 delivered intranasally and lung tissue assessed via immunohistochemistry and pulmonary function testing.
Study Limitations
The study relies solely on cell lines and mouse models; human pharmacokinetic and safety data for intranasal rhCC16 are absent. A549 cells, while widely used, are a cancer-derived line and may not fully represent primary alveolar epithelial biology. Optimal dosing regimens, delivery frequency, and long-term efficacy have not yet been characterized.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: